

# **Chemotherapy Not Otherwise Classified Agents: J9999**

Prior Authorization Request Medicare Part B Form

Instructions: \* Indicates required information – Form may be returned if required information is not provided. Please fax this request to the appropriate fax number listed at the bottom of the page.

□ NEW START - Start Date:				Continuation (within 365 days):  Date of last treatment					
	Date Req	uested							
	Requestor Clinic name:						9	/ Fax	
	MEMBER INFORMATION								
*Na	*Name: *ID#: *DOB:								
PRESCRIBER INFORMATION									
*Na	*Name:								
*Add	dress:				*Fax:				
		DIS	PENSING PROVIDER	ADM	INISTRA	ATION INFOR	MATION		
*Na	me:					Ph	one:		
*Add	dress:						X:		
		ı	PROCEDURE / F	PROD	UCT INF	ORMATION		1	ı
НС	PC Code	Name of Drug	☐ Self-administered	Dos	e (Wt:	kg Ht:	)	Frequency	End Date if known
	hart notes	attached. Othe	er important informat	ion:_					
Diagnosis: ICD10: Description:									
□ Provider attests the diagnosis provided is an FDA-Approved indication for this drug									
			CLINICA	L INF	ORMAT	ION			
□ New Start or Initial Request: (Clinical documentation required for all requests) □ Provider has reviewed the attached "Criteria for Approval" and attests the member meets ALL required PA criteria.  If not, please provide clinical rationale for formulary exception:									
<ul> <li>□ Continuation Requests: (Clinical documentation required for all requests)</li> <li>□ Provider has reviewed the attached "Criteria for Continuation" and attests the member meets         ALL required PA Continuation criteria.</li> <li>□ Patient had an adequate response or significant improvement while on this medication.         If not, please provide clinical rationale for continuing this medication:</li></ul>									
ACKNOWLEDGEMENT									
Request By (Signature Required):									



## Prior Authorization Group - Chemotherapy Not Otherwise Classified Agents PA

### Drug Name(s):

#### **UNCLASSIFIED CHEMOTHERAPY DRUGS**

#### Criteria for approval of Prior Authorization Drug:

- 1. Prescribed for an approved FDA diagnosis (as listed below):
- 2. Prescribed by, or in consultation with an oncologist or other cancer specialist related to the diagnosis.
- 3. Drug is being used appropriately per NCCN or other cancer-related guidelines.
- 4. Member does not have any clinically relevant contraindications, or CMS/Plan exclusions, to the requested drug.
- If the member meets all these criteria, they may be approved by the Plan for the requested drug.
- Quantity limits and Tiering will be determined by the Plan.

		O 14	
<b>LVC</b>	lusion	( rita	ria
	lusivii	UIILE	Ha.

N/A

**Prescriber Restrictions:** 

N/A

**Coverage Duration:** 

New Start: Approval will be for 6 months Continuation: Approval will be for 12 months

**FDA Indications:** 

As per FDA approved resources

Off-Label Uses:

N/A

**Age Restrictions:** 

N/A

Other Clinical Considerations:

N/A

Resources:

https://www.nccn.org/home/